Business
Director/PDMR Share Purchase
Renalytix plc announced that Joel Jung, interim Chief Financial Officer, purchased 2,000 American Depositary Shares (ADS) at $2.90 per ADS on February 11, 2026, for a total transaction value of $5,800. Following this purchase, Mr. Jung holds an interest in 308,855 Ordinary Shares, representing 0.07% of the company's issued share capital. This transaction indicates insider confidence in the company's performance and prospects. Disclaimer*
About this update from Renalytix Plc
[{"type":"text","content":"\n\n\n \nRenalytix plc\n(\"Renalytix\" or the \"Company\")\n \nDirector / PDMR Share Purchase\n \nLONDON and NEW YORK, 12 February 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, whose product kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test to support early-stage risk assessment in chronic diabetic kidney disease, announces that on 11 February 2026 Joel Jung, interim Chief Financial Officer, bought 2,000 American Depositary Shares (ADS) at a price of US$2.90 per ADS. ADS consist of 50 Ordinary Shares of £0.0025 each.\n \nFollowing this transaction, Joel Jung is interested in 308,855 Ordinary Shares representing 0.07% of the issued share capital of the Company.\n \nFor further information, please contact:\n \n\n\n\n\nRenalytix plc\n\n\nwww.renalytix.com\n\n\n\n\nJames McCullough, CEO\n\n\nVia Walbrook PR\n\n\n\n\n\n\n\n\n\n\n\n\nSP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)\n\n\nTel: +44 (0)20 3470 0470\n\n\n\n\nJeff Keating / David Hignell (Corporate Finance)\nVadim Alexandre (Corporate Broking)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nOberon Capital (Joint Broker)\n\n\nTel: +44 (0)20 3179 5300\n\n\n\n\nMike Seabrook / Nick Lovering\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR Limited\n\n\nTel: +44 (0)20 7933 8780 or [email protected]\n\n\n\n\nPaul McManus / Alice Woodings\n\n\nMob: +44 (0)7980 541 893 / +44 (0)7407 804 654\n\n\n\n\n\n\n\n\n\n\n \nAbout Renalytix (www.renalytix.com)\nRenalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for kidneyintelX.dkd which is now offered commercially in the United States.\n \nUnrecognized and uncontrolled diabetic kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom's medical system, affecting approximately 15 million and 8 million people, respectively. After five years of development and clinical validation, kidneyintelX.dkd is the only FDA-approved and Medicare-reimbursed prognostic tool capable of understanding a patient's risk with diabetic kidney disease early where trea...